Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 88 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 88 mikrog
Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 100 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 100 mikrog
Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 112 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 112 mikrog
Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 125 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 125 mikrog
Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 137 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 137 mikrog
Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 150 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 150 mikrog
Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 175 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 175 mikrog
Norwegen -
Norwegisch -
Statens legemiddelverk
tirosintsol 200 mikrog
ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 200 mikrog
Europäische Union -
Norwegisch -
EMA (European Medicines Agency)
adrovance
n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - osteoporose, postmenopausale - legemidler til behandling av bein sykdommer - behandling av postmenopausal osteoporose hos pasienter med risiko for vitamin d-mangel. adrovance reduserer risikoen for vertebrale og hoftebrudd.
Europäische Union -
Norwegisch -
EMA (European Medicines Agency)
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.